Usability of the Novel Liraglutide 3.0 mg Pen Injector among Overweight or Obese Adult Patients with or Without Prior Injection Experience

Journal of Diabetes Science and Technology

Volumn 10, Issue 1, 2016, Pages 164-174

  Fujioka, Ken ^a   Sparre, Thomas ^b   Sun, Lily Yong Hui ^b   Krogsgaard, Susanne ^b   Kushner, Robert F ^c  

^a SCRIPPS CLINIC   (United States)

^b NOVO NORDISK A S   (Denmark)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

liraglutide; obesity; pen injector; pharmacotherapy; usability testing

Indexed keywords

LIRAGLUTIDE; ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DEVICE SAFETY; DIABETES EDUCATION; DYSLIPIDEMIA; FEMALE; HEALTH CARE PERSONNEL; HUMAN; HYPERTENSION; LIRAGLUTIDE PEN INJECTOR; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE; MEDICATION ERROR; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RISK ASSESSMENT; TASK PERFORMANCE; DEVICES; DISPOSABLE EQUIPMENT; DRUG SELF ADMINISTRATION; MEDICAL EDUCATION; MIDDLE AGED; OVERWEIGHT; PATIENT EDUCATION; SUBCUTANEOUS DRUG ADMINISTRATION; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; DISPOSABLE EQUIPMENT; EDUCATION, MEDICAL; FEMALE; HEALTH PERSONNEL; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; LIRAGLUTIDE; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; PATIENT EDUCATION AS TOPIC; SELF ADMINISTRATION; YOUNG ADULT;

EID: 85009145035     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/1932296815593295     Document Type: Article

References (40)

1. Kelly T, Yang W, Chen CS, Reynolds K, He J,. Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond). 2008; 32 (9): 1431-1437.
2. Cawley J, Meyerhoefer C,. The medical care costs of obesity: an instrumental variables approach. J Health Econ. 2012; 31 (1): 219-230.
3. Malnick SD, Knobler H,. The medical complications of obesity. QJM. 2006; 99: 565-579.
4. Nagai M, Kuriyama S, Kakizaki M, et al. Impact of obesity, overweight and underweight on life expectancy and lifetime medical expenditures: the Ohsaki Cohort Study. BMJ Open. 2012; 2 (3): e000940.
5. Whitlock G, Lewington S, Sherliker P, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009; 373: 1083-1096.
6. Soltoft F, Hammer M, Kragh N,. The association of body mass index and health-related quality of life in the general population: data from the 2003 Health Survey of England. Qual Life Res. 200;18(10): 1293-1299.
7. Ul-Haq Z, Mackay DF, Fenwick E, Pell JP,. Meta-analysis of the association between body mass index and health-related quality of life among adults, assessed by the SF-36. Obesity (Silver Spring). 2013; 21 (3): E322-E327.
8. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015; 100 (2): 342-362.
9. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Obesity Society. J Am Coll Cardiol. 2014; 63 (25 pt B): 2985-3023.
10. Dombrowski SU, Knittle K, Avenell A, Araújo-Soares V, Sniehotta FF,. Long term maintenance of weight loss with non-surgical interventions in obese adults: systematic review and meta-analyses of randomised controlled trials. BMJ. 2014; 348: g2646.
11. Mann T, Tomiyama AJ, Westling E, Lew AM, Samuels B, Chatman J,. Medicare's search for effective obesity treatments: diets are not the answer. Am Psychol. 2007; 62 (3): 220-233.
12. Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011; 365 (17): 1597-1604.
13. Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med. 2005; 353 (20): 2111-2120.
14. FDA. 2012. Victoza (liraglutide): prescribing information: http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/022341s007s009s013lbl.pdf. Accessed May 22, 2015.
15. Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond). 2012; 36 (6): 843-854.
16. Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 2013; 37 (11): 1443-1451.
17. FDA. Saxenda (liraglutide): prescribing information. 2014: http://www.drugs.com/pro/saxenda.html. Accessed May 22, 2015.
18. EMA. Saxenda (liraglutide): summary of product characteristics. 2015: http://www.ema.europa.eu/ema/index.jsp?curl=/pages/medicines/human/medicines/003780/human-med-001855.jsp. Accessed May 22, 2015.
19. Asakura T, Seino H, Nakano R, et al. A comparison of the handling and accuracy of syringe and vial versus prefilled insulin pen (FlexPen). Diabetes Technol Ther. 2009; 11 (10): 657-661.
20. Keith K, Nicholson D, Rogers D,. Accuracy and precision of low-dose insulin administration using syringes, pen injectors, and a pump. Clin Pediatr (Phila). 2004; 43 (1): 69-74.
21. Selam JL,. Evolution of diabetes insulin delivery devices. J Diabetes Sci Technol. 2010; 4 (3): 505-513.
22. Food and Drug Administration. Design considerations for devices intended for home use. 2014: http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM331681.pdf. Accessed February 16, 2015.
23. Buysman E, Conner C, Aagren M, Bouchard J, Liu F,. Adherence and persistence to a regimen of basal insulin in a pre-filled pen compared to vial/syringe in insulin-naive patients with type 2 diabetes. Curr Med Res Opin. 2011; 27 (9): 1709-1717.
24. Graff MR, McClanahan MA,. Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe. Clin Ther. 1998; 20 (3): 486-496.
25. Korytkowski M, Bell D, Jacobsen C, Suwannasari R,. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther. 2003; 25 (11): 2836-2848.
26. Korytkowski M, Niskanen L, Asakura T,. FlexPen: addressing issues of confidence and convenience in insulin delivery. Clin Ther. 2005; 2 (suppl B): S89-S100.
27. Summers KH, Szeinbach SL, Lenox SM,. Preference for insulin delivery systems among current insulin users and nonusers. Clin Ther. 2004; 26 (9): 1498-1505.
28. Rubin RR, Peyrot M,. Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategies. Diabetes Care. 200427 (10): 2495-2497.
29. Asakura T, Jensen KH,. Comparison of intuitiveness, ease of use, and preference in two insulin pens. J Diabetes Sci Technol. 2009; 3 (2): 312-319.
30. Reimer T, Hohberg C, Pfützner AH, Jørgensen C, Jensen KH, Pfützner A,. Intuitiveness, instruction time, and patient acceptance of a prefilled insulin delivery device and a reusable insulin delivery device in a randomized, open-label, crossover handling study in patients with type 2 diabetes. Clin Ther. 2008; 30 (12): 2252-2262.
31. American National Standards Institute/Association for the Advancement of Medical Instrumentation. HE75: Human factors engineering-design of medical devices. 2009: http://my.aami.org/aamiresources/previewfiles/HE75-1311-preview.pdf. Accessed April 13, 2015.
32. International Electrotechnical Commission. 62366: Medical devices-application of usability engineering to medical devices. 2007: https://www.iso.org/obp/ui/#iso:std:iec:62366:ed-1:v1:en. Accessed April 13, 2015.
33. Food and Drug Administration. Medical device safety-incorporating human factors engineering into risk management. 2000: http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm094460.htm. Accessed April 13, 2015.
34. Dromgoole P, Gallichan M, Nute B, O'Brien S, Preston F, Tipson M,. Starting injectable treatment in adults with type 2 diabetes: RCN guidance for nurses. 2014: http://www.rcn.org.uk/-data/assets/pdf-file/0009/78606/002254.pdf. Accessed February 16, 2015.
35. Bailey T, Thurman J, Niemeyer M, Schmeisl G,. Usability and preference evaluation of a prefilled insulin pen with a novel injection mechanism by people with diabetes and healthcare professionals. Curr Med Res Opin. 2011; 27 (10): 2043-2052.
36. ® for the delivery of insulin: technical attributes and perception among patients and healthcare professionals. Expert Rev Med Devices. 2012; 9 (3): 209-217.
37. Oyer D, Narendran P, Qvist M, Niemeyer M, Nadeau DA,. Ease of use and preference of a new versus widely available prefilled insulin pen assessed by people with diabetes, physicians and nurses. Expert Opin Drug Deliv. 2011; 8 (10): 1259-1269.
38. Nadeau DA, Campos C, Niemeyer M, Bailey T,. Healthcare professional and patient assessment of a new prefilled insulin pen versus two widely available prefilled insulin pens for ease of use, teaching and learning. Curr Med Res Opin. 2012; 28 (1): 3-13.
39. Pearson TL,. Practical aspects of insulin pen devices. J Diabetes Sci Technol. 2010; 4 (3): 522-531.
40. Spollett G,. Insulin devices: addressing barriers to insulin therapy with the ideal pen. Diabetes Educ. 2008; 34 (6): 957-960, 963, 967.